These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 2263613

  • 21. Interleukin-12-based immunotherapy against rat 9L glioma.
    Jean WC, Spellman SR, Wallenfriedman MA, Hall WA, Low WC.
    Neurosurgery; 1998 Apr; 42(4):850-6; discussion 856-7. PubMed ID: 9574650
    [Abstract] [Full Text] [Related]

  • 22. Adoptive cell transfer therapy for malignant gliomas.
    Ishikawa E, Takano S, Ohno T, Tsuboi K.
    Adv Exp Med Biol; 2012 Apr; 746():109-20. PubMed ID: 22639163
    [Abstract] [Full Text] [Related]

  • 23. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
    Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM.
    J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells.
    Kikuchi T, Joki T, Abe T, Ohno T.
    J Immunother; 1999 May; 22(3):245-50. PubMed ID: 10335484
    [Abstract] [Full Text] [Related]

  • 26. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y.
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [Abstract] [Full Text] [Related]

  • 27. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes.
    Schiltz PM, Gomez GG, Read SB, Kulprathipanja NV, Kruse CA.
    J Interferon Cytokine Res; 2002 Dec; 22(12):1209-16. PubMed ID: 12581494
    [Abstract] [Full Text] [Related]

  • 28. Differentiation of glioma and radiation injury in rats using in vitro produce magnetically labeled cytotoxic T-cells and MRI.
    Arbab AS, Janic B, Jafari-Khouzani K, Iskander AS, Kumar S, Varma NR, Knight RA, Soltanian-Zadeh H, Brown SL, Frank JA.
    PLoS One; 2010 Feb 26; 5(2):e9365. PubMed ID: 20195476
    [Abstract] [Full Text] [Related]

  • 29. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R, Rosenberg SA.
    J Immunol; 1985 Dec 26; 135(6):4273-80. PubMed ID: 3877766
    [Abstract] [Full Text] [Related]

  • 30. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.
    Rice CD, Baldwin NG, Biron RT, Bear HD, Merchant RE.
    J Neurooncol; 1997 Mar 26; 32(1):29-38. PubMed ID: 9049860
    [Abstract] [Full Text] [Related]

  • 31. Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies.
    Jacobs SK, Wilson DJ, Melin G, Parham CW, Holcomb B, Kornblith PL, Grimm EA.
    Neurol Res; 1986 Jun 26; 8(2):81-7. PubMed ID: 2875409
    [Abstract] [Full Text] [Related]

  • 32. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
    Kruse CA, Visonneau S, Kleinschmidt-DeMasters BK, Gup CJ, Gomez GG, Paul DB, Santoli D.
    Cancer Res; 2000 Oct 15; 60(20):5731-9. PubMed ID: 11059767
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Gamma interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes.
    Paul DB, Read SB, Kulprathipanja NV, Gomez GG, Kleinschmidt-DeMasters BK, Schiltz PM, Kruse CA.
    J Neurooncol; 2003 Oct 15; 64(1-2):89-99. PubMed ID: 12952290
    [Abstract] [Full Text] [Related]

  • 36. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
    Schwarz RE, Vujanovic NL, Hiserodt JC.
    Cancer Res; 1989 Mar 15; 49(6):1441-6. PubMed ID: 2784350
    [Abstract] [Full Text] [Related]

  • 37. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y.
    Hum Cell; 1992 Sep 15; 5(3):226-35. PubMed ID: 1467321
    [Abstract] [Full Text] [Related]

  • 38. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL, Herberman RB, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):878-83. PubMed ID: 3257411
    [Abstract] [Full Text] [Related]

  • 39. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.
    Kruse CA, Mitchell DH, Lillehei KO, Johnson SD, McCleary EL, Moore GE, Waldrop S, Mierau GW.
    Cancer; 1989 Oct 15; 64(8):1629-37. PubMed ID: 2790675
    [Abstract] [Full Text] [Related]

  • 40. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
    Yoshida S, Tanaka R, Takai N, Ono K.
    Cancer Res; 1988 Sep 01; 48(17):5011-6. PubMed ID: 3261631
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.